title: Salutary effects of 17beta-estradiol on Peyer's patch T cell functions following trauma-hemorrhage.
abstract: Although 17beta-estradiol (E2) administration following trauma-hemorrhage (T-H) improves immune functions in male rodents, it remains unclear whether E2 has salutary effects on Peyer's patch (PP) T cell functions. We hypothesized that T-H induces PP T cell dysfunction and E2 administration following T-H will improve PP T cell function. T-H was induced in male C3H/HeN mice (6-8weeks) by midline laparotomy and approximately 90min of hemorrhagic shock (blood pressure 35mmHg), followed by fluid resuscitation (4x the shed blood volume in the form of Ringer's lactate). Estrogen receptor (ER)-alpha agonist propyl pyrazole triol (PPT; 5microg/kg), ER-beta agonist diarylpropionitrile (DPN; 5microg/kg), E2 (50microg/kg), or vehicle was injected subcutaneously at resuscitation onset. Two hours later, mice were sacrificed and PP T cells isolated. PP T cell capacity to produce cytokines in response to in vitro stimulation, PP T cell proliferation and MAPK (p38, ERK-1/2, JNK) activation were measured. Results indicate PP T cell proliferation, cytokine production and MAPK activation decreased significantly following T-H. E2, PPT or DPN administration normalized these parameters. Since PPT or DPN administration following T-H was effective in normalizing PP T cell functions, the salutary effects of E2 are mediated via ER-alpha and ER-beta.
authors.affiliation: Center for Surgical Research and Department of Surgery, University of Alabama at Birmingham, G094 Volker Hall, 1670 University Boulevard, Birmingham, AL 35294, USA.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kawasaki
authors.forename: Takao
authors.initials: T
authors.lastname: Suzuki
authors.forename: Mashkoor A
authors.initials: MA
authors.lastname: Choudhry
authors.forename: Kirby I
authors.initials: KI
authors.lastname: Bland
authors.forename: Irshad H
authors.initials: IH
authors.lastname: Chaudry
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D004958:Estradiol / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000819:agonists; D047629:Estrogen Receptor beta / Q000819:agonists; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009570:Nitriles / Q000494:pharmacology; D010581:Peyer's Patches / Q000166:cytology* / Q000187:drug effects; D010636:Phenols; D011422:Propionates / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D012771:Shock, Hemorrhagic / Q000503:physiopathology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000502:physiology*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: C486182:2,3-bis(4-hydroxyphenyl)-propionitrile; D016207:Cytokines; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D009570:Nitriles; D010636:Phenols; D011422:Propionates; D011720:Pyrazoles; C486184:4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol; D004958:Estradiol; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases
references.citation: Endocrinology. 1997 Jul;138(7):2919-27
references.pmid: 9202236
references.citation: Ann Surg. 1999 May;229(5):662-7; discussion 667-8
references.pmid: 10235524
references.citation: Mol Immunol. 2008 Jan;45(2):376-85
references.pmid: 17673296
references.citation: Eur J Surg. 1996 Apr;162(4):259-73
references.pmid: 8739412
references.citation: Am J Surg. 1993 Feb;165(2A Suppl):59S-67S
references.pmid: 8439001
references.citation: Crit Care Med. 2000 Apr;28(4 Suppl):N67-77
references.pmid: 10807318
references.citation: Immunology. 2000 Mar;99(3):464-72
references.pmid: 10712678
references.citation: J Biol Chem. 2000 Jun 2;275(22):16513-7
references.pmid: 10748182
references.citation: Infect Immun. 1980 Feb;27(2):461-7
references.pmid: 6966611
references.citation: Clin Exp Immunol. 1998 Sep;113(3):429-37
references.pmid: 9737673
references.citation: J Lab Clin Med. 1980 Jun;95(6):857-67
references.pmid: 6966670
references.citation: Annu Rev Immunol. 2002;20:761-94
references.pmid: 11861617
references.citation: Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44
references.pmid: 15187187
references.citation: J Leukoc Biol. 2006 May;79(5):963-70
references.pmid: 16478916
references.citation: Cell Signal. 2009 Aug;21(8):1298-307
references.pmid: 19324083
references.citation: Shock. 2007 Mar;27(3):320-5
references.pmid: 17304114
references.citation: Am J Physiol. 1999 Jul;277(1):C35-42
references.pmid: 10409106
references.citation: J Immunol. 1993 Oct 1;151(7):3521-9
references.pmid: 8376790
references.citation: Immunol Rev. 2009 Mar;228(1):212-24
references.pmid: 19290930
references.citation: Immunol Cell Biol. 1995 Dec;73(6):484-8
references.pmid: 8713469
references.citation: Shock. 2004 May;21(5):391-400
references.pmid: 15087814
references.citation: J Leukoc Biol. 2005 Jan;77(1):16-23
references.pmid: 15496450
references.citation: Endocrinology. 2002 Nov;143(11):4172-7
references.pmid: 12399409
references.citation: Biochim Biophys Acta. 2005 Jun 30;1741(1-2):113-9
references.pmid: 15955454
references.citation: Trends Mol Med. 2005 Feb;11(2):56-63
references.pmid: 15694867
references.citation: Shock. 2005 Jun;23(6):527-32
references.pmid: 15897805
references.citation: Cytokine. 2008 Apr;42(1):32-8
references.pmid: 18343154
references.citation: Shock. 2000 Aug;14(2):81-90
references.pmid: 10947147
references.citation: Crit Care Med. 2001 Dec;29(12):2245-50
references.pmid: 11801815
references.citation: Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G937-47
references.pmid: 12016118
references.citation: J Mol Cell Cardiol. 1997 Oct;29(10):2849-54
references.pmid: 9344778
references.citation: Trends Endocrinol Metab. 2002 Jul;13(5):220-5
references.pmid: 12185669
references.citation: Intensive Care Med. 2005 May;31(5):709-17
references.pmid: 15782315
references.citation: Shock. 2006 Nov;26(5):438-49
references.pmid: 17047513
references.citation: Shock. 2005 Dec;24(6):505-7
references.pmid: 16317378
references.citation: J Appl Physiol (1985). 2007 Jan;102(1):163-8
references.pmid: 17023568
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L1004-9
references.pmid: 16361351
references.citation: J Leukoc Biol. 2004 Mar;75(3):400-7
references.pmid: 14557385
references.citation: Blood. 2000 Mar 15;95(6):2059-67
references.pmid: 10706875
references.citation: Shock. 2005 Feb;23(2):115-22
references.pmid: 15665725
references.citation: Shock. 1994 Apr;1(4):267-72
references.pmid: 7735960
references.citation: J Biol Chem. 2005 Aug 19;280(33):29409-19
references.pmid: 15975924
references.citation: Gen Pharmacol. 2000 Jul;35(1):1-9
references.pmid: 11679199
references.citation: Annu Rev Immunol. 2000;18:275-308
references.pmid: 10837060
references.citation: Immunol Cell Biol. 1995 Oct;73(5):389-96
references.pmid: 8595915
references.citation: Shock. 2005 Dec;24 Suppl 1:101-6
references.pmid: 16374381
references.citation: Endocr Metab Immune Disord Drug Targets. 2006 Jun;6(2):127-35
references.pmid: 16787286
references.citation: Clinics (Sao Paulo). 2006 Oct;61(5):479-88
references.pmid: 17072448
references.citation: J Leukoc Biol. 2005 Aug;78(2):565-73
references.pmid: 15857937
references.citation: Cytokine. 2006 Nov;36(3-4):107-14
references.pmid: 17207634
references.citation: Crit Care Med. 2006 Jan;34(1):182-7
references.pmid: 16374173